NewsRSS2 days ago
A person who was diagnosed with limb-girdle muscular dystrophy 30 years ago finally took a genetic test to find out exactly which gene mutation caused their condition. Genetic testing can help doctors understand the specific type of muscular dystrophy a patient has, which may affect treatment options and family planning decisions. This story shows how genetic testing technology has improved over time and can provide answers even decades after an initial diagnosis.
WHY IT MATTERSGenetic confirmation of limb-girdle muscular dystrophy can unlock access to gene-specific clinical trials and emerging therapies that weren't available at the time of initial diagnosis.
NewsRSS2 days ago
This article is a quiz about nerandomilast, a medicine being studied to treat progressive pulmonary fibrosis (PPF), which is a lung disease where lung tissue becomes scarred and stiff over time, making it harder to breathe. The quiz helps patients and caregivers learn more about this potential treatment option. It's a way to test your understanding of how this medicine might help people with this serious lung condition.
WHY IT MATTERSPatients with progressive pulmonary fibrosis have limited treatment options, so learning about emerging therapies like nerandomilast helps them stay informed about potential new ways to slow lung damage.
PolicyRSSApr 16
The FDA is inviting companies that make testosterone replacement therapy drugs to apply for approval of a new use: treating low sex drive in men with a specific condition called idiopathic hypogonadism (when the body doesn't make enough testosterone for unknown reasons). This is an early step that could lead to new treatment options for men with this condition.
WHY IT MATTERSMen with idiopathic hypogonadism who experience low libido may soon have an FDA-approved treatment option specifically designed for this symptom, rather than relying on off-label use of existing testosterone therapies.
🔴 BreakingDrug approvalRSSApr 3
The FDA has approved a new treatment called Kresladi for a rare immune system disorder called Leukocyte Adhesion Deficiency Type I (LAD-I). This treatment works by using gene therapy, which means it fixes the faulty gene that causes the disease. This is the first gene therapy approved for this specific condition, giving patients with LAD-I a new treatment option.
WHY IT MATTERSPatients with severe LAD-I now have access to the first FDA-approved gene therapy for their condition, which could potentially offer a cure rather than just managing symptoms.
🔴 BreakingDrug approvalRSSApr 3
The FDA has approved a new drug called Avlayah to treat Hunter syndrome, a rare genetic disease that affects the brain and nervous system. Hunter syndrome happens when the body can't break down certain substances properly, causing serious health problems over time. This approval means patients with Hunter syndrome now have a new treatment option available to help manage the neurologic symptoms of their condition.
WHY IT MATTERSThis is the first FDA approval of Avlayah specifically for the neurologic manifestations of Hunter syndrome, offering patients a new therapeutic option for managing brain and nervous system symptoms that were previously difficult to treat.
🔴 BreakingDrug approvalOPENFDAApr 3
The FDA has approved a new medication called LIFYORLI (relacorilant) made by Corcept Therapeutics. This drug was officially approved on March 25, 2026. LIFYORLI is a new treatment option that is now available for patients who need it.
WHY IT MATTERSThis approval marks the availability of a new treatment option for patients with Cushing's syndrome, a serious hormonal disorder where the body produces too much cortisol.
ResearchBIORXIVApr 2
Researchers discovered that mutations in a gene called THAP12 cause a severe type of childhood epilepsy called developmental and epileptic encephalopathy. Two siblings with this condition had two broken copies of the THAP12 gene (one from each parent), which stopped the gene from making enough of its protein. This finding helps explain why some children develop severe seizures early in life and could lead to better diagnosis and treatment options.
WHY IT MATTERSFamilies with children diagnosed with infantile spasms or Lennox-Gastaut syndrome now have a new genetic cause to test for, which could explain their child's condition and guide future treatment decisions.
NewsPUBMEDMar 28
This is an editorial article that introduces a special collection of scientific papers about gene therapy for rare diseases. Gene therapy is a treatment that fixes or replaces faulty genes that cause disease. The editorial discusses how gene therapy is becoming an important treatment option for rare diseases that affect small numbers of people.
WHY IT MATTERSThis editorial highlights the growing momentum in gene therapy development for rare diseases, which means more treatment options may become available for conditions that previously had few or no approved therapies.
AdvocacyRSSMar 26
NORD, a major rare disease organization, is partnering with OpenEvidence to create AI-powered tools that help doctors and patients find reliable information about rare diseases. This partnership aims to make it easier for people worldwide to access trustworthy resources about their conditions and treatment options.
WHY IT MATTERSThis partnership could help patients with rare diseases get faster access to accurate, expert-reviewed information from their doctors, potentially reducing diagnostic delays and improving treatment decisions.
ResearchPUBMEDMar 26
Scientists are developing tiny particles called exosomes that can deliver cancer-fighting medicines directly to rare cancer tumors. These natural particles act like delivery trucks, carrying drugs to cancer cells while reducing damage to healthy cells. Early research shows this approach could help rare cancer patients who currently have few treatment options.
WHY IT MATTERSPatients with rare cancers often lack targeted treatments and face delayed diagnoses—exosome-based therapies could provide new options by delivering drugs more effectively to tumors while causing fewer side effects.